Background of Collaboration
Heart failure is a life-shortening disease that gradually worsens as the heart's function declines, causing shortness of breath and swelling. Since the incidence of heart failure increases with age, a "heart failure pandemic" is predicted in Japan, a super-aging society, where the number of patients is expected to increase dramatically.
There are various causes of heart failure, including hypertension, cardiomyopathy, myocardial infarction, valvular disease, and arrhythmia. Since there is an appropriate treatment for each causative disease, close examination of the cause is extremely important in heart failure cases. Cardiac amyloidosis, a rare, progressive, and fatal disease, is one of the most common causes of heart failure. However, the lack of characteristic symptomatic findings and the lack of experience in diagnosis and treatment of this disease make it difficult for many attending physicians to decide whether to refer patients to specialized facilities or not, and thus diagnosis and appropriate treatment often fail to be made. This often results in failure to diagnose and provide appropriate treatment.
Medii offers "E-Consult ®︎," an online specialist consultation service exclusively for physicians, to bring the knowledge and experience of a limited number of specialist physicians to medical practices in need, particularly in the areas of rare and intractable diseases.
Pfizer is committed to improving the diagnosis rate of heart failure patients, including cardiac amyloidosis, in line with its corporate objective to "create breakthroughs that make a significant difference in patients' lives. Pfizer will collaborate on Medii's efforts to share this specialist knowledge.
This collaboration was born out of Pfizer Healthcare Hub Japan, Pfizer's global initiative to collaborate with startup companies to provide better solutions for patients.
*The press releases of both companies at the start of the study can be found at the following link.
Pfizer Japan Pitch Event at the 3rd Pfizer Healthcare Hub Japan|News｜Medii Inc.
■ Third Pfizer Healthcare Hub Japan Pitch Event Held to Discuss Solutions with Startups to Deliver Breakthroughs to Patients - | pfizer.co.jp Press Releases
Together, Medii and Pfizer aim to create a society where all patients have access to more specialized care.
Medii has launched a disease awareness website with information on heart failure and cardiac amyloidosis to provide physicians with the latest information on the disease. Furthermore, by utilizing "E-Consult ®︎," which allows physicians involved in heart failure treatment to consult with specialists online free of charge, the site will lead to early diagnosis and appropriate treatment of heart failure and cardiac amyloidosis. The initiative will initially be launched in the Kinki area and will be expanded nationwide. Pfizer will cooperate in this initiative by introducing "E-Consult ®︎" to specialists and general physicians.
Heart Failure/Cardiac Amyloidosis Awareness Site:https://medii.jp/HF_ATTRCMconsultant/
Medii will also hold seminars for physicians to improve the diagnosis rate of heart failure/ cardiac amyloidosis and provide case information.
What is "E-Consult®"?
E-Consult®" provided and operated by Medii is a completely free online service that allows physicians to consult with specialists outside the hospital or in distant locations. Difficult-to-diagnose or non-specialized cases can be consulted anonymously through the chat function on "E-Consult".
More than 800 specialists recommended by physicians in all specialties cooperate in the response process, and the system notifies and matches the most appropriate specialist according to the content of the consulting physician. The system handles all specialties with a focus on immunological intractable diseases and rare diseases where knowledge is not widely available due to the uneven regional distribution of knowledge.
Pfizer leverages science and global resources to deliver treatments that help people live longer, healthier lives and significantly improve their lives. We strive to establish standards of quality, safety and value in the discovery, development and manufacture of healthcare products, including innovative medicines and vaccines.
Every day, Pfizer employees contribute to the health of people around the world by providing better prevention and treatment for life- and life-threatening diseases. As one of the world's leading innovative pharmaceutical companies, we are committed to working with healthcare professionals, governments, and communities around the world to ensure that everyone has easy access to reliable healthcare. We have been moving forward for more than 170 years to meet people's expectations.
|name of company||Pfizer Japan Inc.|
|Establishment||August 1, 1953|
|Location||Shinjuku Bunka Quint Building, 3-22-7 Yoyogi, Shibuya-ku, Tokyo|
|representative||Akihisa Harada, President and Representative Director|
|Business Overview||Manufacture, sale, import and export of ethical pharmaceuticals|
|uniform resouce locator||www.pfizer.co.jp(Japan Corporation)www.pfizer.com(Global)|
Medii is developing a business to expand the knowledge of medical specialists online, especially in rare and intractable diseases, which are a major challenge. The company name reflects the company's desire to change the structure of medical care from the inside out (Medii: Latin) from the perspective of both physicians and patients.
With the cooperation and support of many medical specialists, we currently provide three services for physicians: "E-Consultation," "Case Bank," and "E-Confirmation," and are pursuing the essence of medicine with the aim of realizing a world where all people can receive better medical care, no matter what region they live in.
|name of company||Medii Corporation|
|Establishment||February 20, 2020|
|Location||Tensho Office Shinjuku 3-chome 202, 5-14-12 Shinjuku, Shinjuku-ku, Tokyo|
|representative||Representative Director Doctor Hiroki Yamada|
|Business Overview||Providing specialist knowledge sharing services|
|uniform resouce locator||https://medii.jp|